Effect of <scp>Lactobacillus rhamnosus</scp> GG on ileal pouch inflammation and microbial flora

Kuisma, Juha; Mentula, Silja; Järvinen, Heikki; Kahri, Arvi; Saxelin, Maija; Färkkilä, M.

doi:10.1046/j.1365-2036.2003.01465.x

Cited by 257 publications

(133 citation statements)

References 33 publications

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…In addition, all patients relapsed within 3 months of stopping the probiotic [120]. Similar effects were observed after application of lactobacilli [121,122].…”

Section: Inflammatory Bowel Disease (Ibd)supporting

confidence: 67%

Probiotics and prebiotics — renaissance of a therapeutic principle

Frič

2007

Open Medicine

View full text Add to dashboard Cite

AbstractProbiotics are nonpathogenic microorganisms mostly of human origin which, when administered in adequate amounts, confer a health benefit on the host and enable to prevent or improve some diseases. Probiotics may be a natural temporary constituent of the resident intestinal microflora, but their concentration is not sufficient for therapeutic purposes. The microbiota, the intestinal epithelium, and the mucosal immune system constitute the gastrointestinal ecosystem. All three components are essential for complete functional and developmental maturity of the system. The viability of intestinal microflora (including probiotic strains) requires the availability of nutritional substrates (prebiotics), i.e. various types of fiber and oligosaccharides. Prebiotics are cleaved by microbial enzymes to numerous substances (short-chain fatty acids, aminoacids, polyamines, growth factors, vitamins and antioxidants) indispensable for metabolic and functional activities of the intestinal mucosa. The principal probiotics in use include lactobacilli, bifidobacteria, some nonpathogenic strains of Escherichia coli, and Saccharomyces boulardii. These microbiota display favourable effects which qualify them for therapeutic use. For this purpose, probiotics have to fulfill a series of requirements verifying their efficacy and safety. Experimental and clinical studies examine the prerequisites for the administration of probiotics in digestive diseases, allergic and atopic affections, as well as in some extraintestinal conditions. Future goals of probiotic application include genomic analysis, controlled postnatal colonisation of the digestive tract, the use of probiotics as carriers of peroral vaccines, and recombinant probiotics with in-situ production and targeted application of therapeutic molecules.

show abstract

“…In addition, all patients relapsed within 3 months of stopping the probiotic [120]. Similar effects were observed after application of lactobacilli [121,122].…”

Section: Inflammatory Bowel Disease (Ibd)supporting

confidence: 67%

Probiotics and prebiotics — renaissance of a therapeutic principle

Frič

2007

Open Medicine

View full text Add to dashboard Cite

show abstract

“…Recent studies have also shown that some bacterial strains or mixtures may have the capacity to promote or reduce intestinal inflammation (19,27). This evidence has led to an increased use of probiotic preparations in the therapy of IBD that usually contain lactobacilli, bifidobacteria, or Escherichia coli strains (8,14,18).…”

mentioning

confidence: 99%

Selecting Lactic Acid Bacteria for Their Safety and Functionality by Use of a Mouse Colitis Model

Daniel

Poiret

Goudercourt

et al. 2006

Appl Environ Microbiol

118

View full text Add to dashboard Cite

Studies showed that specific probiotics might provide therapeutic benefits in inflammatory bowel disease. However, a rigorous screening of new probiotics is needed to study possible adverse interactions with the host, particularly when intended for administration to individuals with certain health risks. In this context, the objective of this study was to investigate the role of three lactobacilli (LAB) on intestinal inflammation and bacterial translocation using variations of the mouse model of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced acute colitis. We first compared the in vitro ability of LAB to survive gastrointestinal tract (GIT) conditions and their ability to persist in the GIT of mice following daily oral administration. As a control, we included a nonprobiotic Lactobacillus paracasei strain, previously isolated from an endocarditis patient. Feeding high doses of LAB strains to healthy and to TNBS-treated mice did not induce any detrimental effect or abnormal translocation of the bacteria. Oral administration of Lactobacillus salivarius Ls-33 had a significant preventive effect on colitis in mice, while Lactobacillus plantarum Lp-115 and Lactobacillus acidophilus NCFM did not. None of the three selected LAB strains translocated to extraintestinal organs of TNBS-treated mice. In contrast, L. paracasei exacerbated colitis under severe inflammatory conditions and translocated to extraintestinal organs. This study showed that evaluations of the safety and functionality of new probiotics are recommended. We conclude that not all lactobacilli have similar effects on intestinal inflammation and that selected probiotics such as L. salivarius Ls-33 may be considered in the prevention or treatment of intestinal inflammation.

show abstract

“…One observational study of patients receiving LGG after pouch formation has reported a lower rate of pouchitis than in historical controls [72]. However, Kuisma et al have found no difference in mean pouchitis scores between placebo and LGG-treated groups at the end of a 3-month study period [73]. Finally, a reduction in endoscopic and clinical disease activity associated with an increase in faecal probiotic species has been demonstrated in 51 patients with pouchitis after surgery for UC who consumed fermented milk containing lactobacilli and bifidobacteria [74].…”

Section: Pouchitismentioning

confidence: 99%